Exhibit 99.1 SenesTech Reports First Quarter 2025 Financial Results 40% Revenue Growth in Evolve , Record Gross Profit Margins of 65%, and Continued Progress Toward Profitability TM SURPRISE, Ariz., May 8, 2025. SenesTech, Inc. (NASDAQ: SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-registered rodent birth control products today announced its financial results for the first quarter ended March 31, 2024. Q1 2025 Highlights Operational and Strategi ...

Core Insights - SenesTech, Inc. reported a 17% increase in revenues for Q1 2025, reaching $485,000 compared to $415,000 in Q1 2024, with Evolve product sales growing 40% year-over-year, now accounting for 79% of total revenue [8][3] - The company achieved a record gross profit margin of 64.5%, up from 32.5% in the same quarter last year [8] - The net loss for Q1 2025 was $1.7 million, slightly improved from a loss of $1.8 million in Q1 2024, while adjusted EBITDA loss improved to $1.5 million from $1.7 million [8] Operational and Strategic Highlights - The Evolve™ Rat and Evolve™ Mouse products are now the largest revenue drivers for SenesTech, reflecting a successful product expansion strategy [3] - E-commerce revenue more than doubled year-over-year, with a 107% increase attributed to improved platform functionality and digital marketing efforts [4] - The company has expanded Evolve deployments in major U.S. municipalities, with positive early adoption in Chicago and a pilot program in New York City [5] International Growth - SenesTech has signed distribution agreements in eleven countries and territories, with product shipments already initiated in The Netherlands, Hong Kong, the UAE, and the Maldives [6] - Regulatory approvals are pending in Australia and New Zealand, with additional launches planned for later in 2025 [6] Financial Performance - The company reported a gross profit of $313,000 for Q1 2025, compared to $135,000 in Q1 2024, indicating improved operational efficiency [17] - Total current assets increased to $3.164 million as of March 31, 2025, up from $2.813 million at the end of 2024 [16] - The company has lowered its breakeven revenue threshold from $12 million to approximately $7 million, indicating a path toward positive cash flow [6]

Company Overview - SenesTech, Inc. is a leader in fertility control for managing animal pest populations, having developed products like ContraPest and Evolve, which are designed to be humane, effective, and sustainable [5]. - The company has entered into an exclusive distribution agreement with Asa Jaya Mandiri LTD (AJM) for the commercialization of Evolve™ in Indonesia, marking its eleventh international distribution agreement [1][4]. Industry Context - Rats are a significant threat to palm oil plantations in Indonesia, causing estimated yield reductions of 5-10% annually, which translates to potential economic losses of USD 540 million to USD 1.08 billion each year, given the palm oil market's value of approximately USD 10.8 billion in 2024 [2]. - The rapid reproduction and adaptability of rats to traditional control methods make long-term population management challenging, highlighting the need for effective fertility control solutions [3]. AJM Profile - Asa Jaya Mandiri LTD (AJM) is a prominent Indonesian trading company with a specialized pest management operation, committed to high quality and standards in its offerings [4][7]. - AJM has over a decade of experience and a diverse portfolio of products sourced globally, enabling it to cater to the unique needs of its customers [7].

Financial Results Announcement - SenesTech, Inc. will report its first quarter 2025 financial results after market close on May 8, 2025 [1] - A conference call is scheduled for the same day at 5:00 p.m. Eastern time to review the results [1] Conference Call Details - Interested parties can access the conference call by dialing (844) 308-3351 or (412) 317-5407 [2] - A live webcast of the conference call will be available on the Company's website [2] Replay Information - A teleconference replay will be available for seven days after the call [3] - A webcast replay will be accessible for 90 days on the Company's website [3] Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control [4] - The company has developed ContraPest, the only U.S. EPA-registered contraceptive for rats, and other minimum risk contraceptives for rodents [4] - The mission is to provide proactive, safe, and sustainable pest management solutions [4]

Core Insights - SenesTech, Inc. is expanding the deployment of its Evolve™ Rat Birth Control in the Wicker Park Bucktown area of Chicago, aiming to manage rodent populations without harmful toxins [1][2] - The initiative is a collaboration between SenesTech and local commerce groups, highlighting a joint effort to address urban pest control challenges [5] - Recent media coverage has noted similar deployments in other urban areas, including a pilot program in New York City and initiatives in Boston and Baltimore [3] Company Overview - SenesTech focuses on humane pest management through fertility control, with products designed to integrate into existing pest management programs, enhancing effectiveness while reducing reliance on traditional poisons [6] - The company aims to create healthier environments and cleaner cities through its innovative solutions [6] Community Engagement - A dedicated informational website has been launched for residents and business owners in the Wicker Park Bucktown area to provide updates and information about the Evolve™ program [4] - Early reports on the consumption of Evolve™ Rat indicate positive feedback, and the company is preparing for further shipments as the deployment area expands [5]

Core Insights - SenesTech, Inc. is participating in a webcast fireside chat at the Lytham Partners 2025 Industrials & Basic Materials Investor Summit on April 1, 2025 [1][2] - The company focuses on humane fertility control solutions for managing rodent populations, aiming to create healthier environments [3] Company Overview - SenesTech's products, such as Evolve rodent birth control, enhance pest management programs while reducing reliance on traditional poisons [3] - The company's mission includes creating cleaner cities, more efficient businesses, and healthier communities through humane and sustainable products [3] Event Details - The fireside chat is scheduled for 3:00 p.m. ET on April 1, 2025, and will be accessible via the conference home page [2] - A replay of the chat will be available through the same links, and one-on-one investor meetings can be arranged upon request [2]

Financial Data and Key Metrics Changes - The company reported a 70% increase in quarterly revenues, reaching a record of $501,000 for Q4 2024, and a 56% increase in annual revenue to $1.9 million [27][8] - Quarterly gross profit margins improved to 61%, up from 44% in the same quarter last year, with gross profit dollars increasing by 136% [31][27] - The adjusted EBITDA loss for the quarter was the smallest in company history, with cash burn expected to decrease from $1.5 million to $1 million per quarter [9][34] Business Line Data and Key Metrics Changes - Evolve Rat accounted for 52% of Q4 sales, with a 365% increase compared to the same quarter last year, while Evolve Mouse represented 24% of sales [27][28] - The historical ContraPest product saw a 51% decline in sales as customers transitioned to Evolve solutions [28] Market Data and Key Metrics Changes - E-commerce sales surged by 206% in Q4 2024, making up 55% of total revenue for the quarter [29][13] - The company has signed distribution agreements in 10 countries, with product shipments already made to Hong Kong, UAE, Netherlands, and Maldives [19][20] Company Strategy and Development Direction - The company aims to achieve cash flow breakeven at an annual revenue threshold of $7 million, down from $12 million historically [9] - Strategic financing completed recently is expected to provide necessary capital to accelerate progress towards profitability [10][25] - Focus areas include expanding e-commerce, municipal programs, and international distribution, with a particular emphasis on the warehousing and distribution sector [16][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory, highlighting the successful launch of Evolve products and the positive reception in various markets [11][37] - The company is committed to executing a focused strategy to achieve sustainable long-term success and profitability [36] Other Important Information - The company is implementing cost reduction initiatives expected to lower cash burn by $2 million annually [9] - A new, larger facility in Phoenix is being secured to meet increasing demand without significantly raising facility costs [32] Q&A Session Summary Question: What is the potential growth from the New York pilot program? - Management indicated that the pilot program's success could lead to expansion into additional areas based on initial results [44] Question: What are the sales efforts in the warehousing sector? - The company is moving into ordering pallets of material for deployment in warehousing facilities, indicating a significant market opportunity [46] Question: How is e-commerce contributing to sales? - Management confirmed that advertising and search engine optimization efforts are driving e-commerce sales, which have become a major revenue channel [48] Question: What is the expected contribution from the Lure bait dispenser? - The Lure bait dispenser is seen as a valuable accessory that allows for product use in hard-to-reach areas, generating interest and orders [54] Question: What is the revenue forecast for 2025? - Management refrained from providing specific revenue forecasts but noted that efforts from 2024 are expected to yield results in 2025 [66] Question: What traction has been gained with big box retailers? - The company has seen significant interest from Ace Hardware and is under consideration for warehouse stocking, with orders increasing substantially [68]

Financial Data and Key Metrics Changes - The company reported a record quarterly revenue increase of 70%, reaching $501,000 for Q4 2024, and a 56% increase in annual revenue to $1.9 million [27][8] - Gross profit margins improved to 61% in Q4 2024, up from 44% in the same quarter last year, with gross profit dollars increasing by 136% [31][8] - The adjusted EBITDA loss was the smallest in company history, with cash burn expected to decrease from $1.5 million to $1 million per quarter [9][34] Business Line Data and Key Metrics Changes - Evolve Rat accounted for 52% of Q4 sales, with a 365% increase compared to the same quarter last year, while Evolve Mouse represented 24% of sales [27][28] - ContraPest sales decreased by 51% as customers transitioned to Evolve solutions [28] Market Data and Key Metrics Changes - E-commerce sales surged by 206% in Q4 2024, representing 55% of total revenue for the quarter [28][29] - The company expanded its distribution agreements in 10 countries, with significant orders from cities like New York and Baltimore [19][15] Company Strategy and Development Direction - The company aims to achieve cash flow breakeven at an annual revenue threshold of $7 million, down from $12 million historically [9] - Strategic financing completed is expected to accelerate progress towards profitability [10][24] - Focus on expanding into municipal markets, warehousing, and international distribution as key growth drivers [22][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory, highlighting the successful launch of Evolve products and the potential for growth in various markets [11][37] - The company is committed to a focused strategy that emphasizes cost efficiencies and sustainable long-term success [36] Other Important Information - The company is implementing new initiatives to reduce cash burn by $2 million annually and has secured a larger facility to meet increasing demand [9][32] - The introduction of the Lure bait dispenser is expected to enhance product accessibility, although it is not projected to be a high revenue item [53][54] Q&A Session Summary Question: Visibility on New York pilot program - Management indicated that the pilot program in New York will start in April, with potential for expansion based on initial success [42][44] Question: Sales efforts in warehousing and distribution - The company is seeing increased orders from warehousing facilities, particularly in food production, where traditional poisons are not feasible [46][47] Question: E-commerce sales strategy - Management confirmed that advertising and search engine optimization efforts are in place to drive e-commerce sales, with significant growth noted on platforms like Amazon [48][49] Question: Clarification on cash burn reduction - The reduction from $1.5 million to $1 million was clarified as a decrease in cash burn or adjusted EBITDA [50][52] Question: Contribution of Lure bait dispenser - The Lure bait dispenser is seen as a valuable accessory that allows for product use in hard-to-reach areas, generating interest and orders [53][54] Question: Revenue growth from recent contracts - Management noted that regulatory approvals and field trials are necessary before significant revenue contributions can be expected from new contracts [62][64] Question: Traction with big box retailers - The company has seen significant interest from retailers like Ace Hardware, with plans to expand into their warehouses [68][69] Question: Marketing plans for increasing awareness - A comprehensive marketing plan is in place to promote the product's success in municipalities and through social media [71][73] Question: Manufacturing capacity and cost savings - The company has built its supply chain to handle increased demand without constraints, with ongoing efforts to improve manufacturing efficiencies [77][79]

Market Focus and Product Development - The rat control market is considered sufficient for the company's near-term focus[18]. - The company is focused on gaining market acceptance and commercial viability for its products, including ContraPest and Evolve[18]. - The company believes that its technology can be applied to other mammalian species, which may open new market opportunities[21]. - The company expects expenses to continue increasing as commercialization activities advance[18]. - The success of the company's research and development efforts is critical for future performance and product commercialization[21]. Regulatory and Compliance Issues - The company acknowledges the risks associated with obtaining regulatory approval for its product candidates[21]. - The company anticipates that first and second generation anti-coagulant rodenticides will face increased scrutiny and potential restrictions[18]. - The company asserts that Evolve qualifies for exemption from registration as a minimum risk pesticide under EPA regulations[18]. - The company is subject to compliance with Nasdaq's continued listing requirements, which is vital for maintaining its market presence[21]. - The company files reports with the SEC, ensuring transparency and compliance with information requirements[23]. Financial and Operational Risks - The company faces risks that may cause actual results to differ materially from forward-looking statements, including market acceptance of products and regulatory approvals[21]. - The company acknowledges potential product liability lawsuits that could incur substantial liabilities and limit product commercialization[21]. - The company is concerned that raising additional capital may dilute existing stockholders and restrict operations[21]. - The company recognizes that its share price is volatile, which could lead to securities class action litigation[21]. Human Resources and Talent Management - The company plans to utilize stock-based awards to attract and retain talented employees[18]. - Retaining and attracting key personnel is essential for the company's growth and operational development[21]. - The company emphasizes the importance of establishing an effective sales force and marketing infrastructure to generate significant revenue[21]. Research and Field Studies - The company believes that field research demonstrates more than 90% reduction in rat populations when integrated with pest management protocols[18]. - The company aims to establish fertility control as a standard tool in pest management across all verticals[18].

Revenue Growth - Revenue increased 70% to $501,000 in Q4 2024 compared to $295,000 in Q4 2023, driven by a 206% growth in e-commerce[4] - The Evolve™ Rat product contributed approximately 52% of Q4 2024 revenue, while the Evolve™ Mouse contributed 24%[4] Profitability - Gross profit margin improved to 60.9% in Q4 2024 from 43.7% in Q4 2023[4] - Adjusted EBITDA loss for Q4 2024 was $1.1 million, compared to $1.6 million in Q4 2023, marking the smallest quarterly loss in company history[4][7] Operating Expenses - Operating expenses decreased by 16% in Q4 2024 compared to Q4 2023[4] - The company plans to reduce expenses by approximately $2 million annually through new operating optimization initiatives[6] Net Loss - Net loss for Q4 2024 was $1.3 million, an improvement from a net loss of $1.7 million in Q4 2023[4] Cash Flow Breakeven - The revenue threshold for cash flow breakeven is expected to decrease to approximately $7 million annually, down from $12 million[6] Distribution and Packaging - The company has signed agreements for distribution of Evolve in 10 countries, with product shipments already occurring in Hong Kong, UAE, Netherlands, and Maldives[9] - The company launched new packaging options that use 87% less plastic than traditional pails, enhancing gross margins[9]